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INTRODUCTION 
Juvenile dermatomyositis 
Juvenile dermatomyositis (JDM) is a rare disease with annual incidence of 1.9 -3.2 
/million children reported in population based studies in the UK and US ( 1; 2); still, it is 
an important systemic connective tissue disease in childhood. In Norway, the population 
below 18 years is approximately 1 million, which corresponds with 2-4 new cases 
diagnosed each year. Previously, disease course was serious with high mortality. In the 
1960’s Bitnum introduced “the rule of thirds” – 1/3 of the patients died, 1/3 developed 
severe long term functional disabilities and 1/3 recovered ( 3). The last decades, 
prognosis has improved ( 4) and the mortality rate is now 2- 3% ( 5; 6), presumably due 
to treatment with corticosteroids and other immunosuppressive agents. However, 
knowledge of the long term consequences of JDM has been limited. Still 30-61% of 
patients have signs of sustained disease activity and 60-90% develop organ damage 
7.2-16.8 after disease onset ( 4; 5; 7).  
 
Juvenile and adult dermatomyositis (DM) and polymyositis (PM) are idiopathic, 
inflammatory myopathies (IIM). DM and PM are characterized by skeletal muscle 
weakness and inflammation. In contrast to PM, DM has a variety of skin manifestations. 
A number of classification criteria of IIM’s have been published ( 8); other conditions 
classified as IIM’s are overlap myositis, inclusion- body myositis, amyopathic myositis 
and cancer associated myositis. While new, revised criteria are under development, 
Bohan and Peter’s diagnostic criteria for JDM from 1975, are still in use ( 9), based on 
proximal muscle weakness and pathognomonic rash (heliotropic rash in face and 
Gottron’s papules on fingers/knuckles). However, multiple organ affection is well known. 
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Calcinosis is a manifestation of JDM where calcium deposits in tissue can cause 
contractures and pain from nerve entrapment. Ulcerations of the skin and in the 
gastrointestinal tractus can occur and pulmonary dysfunction is also shown often in a 
restrictive, interstitial pattern ( 10). In the pre-cortisone era, gastrointestinal 
haemorrhage with perforation, together with bronchopneumonia and respiratory 
paralysis were the major causes of death in JDM ( 3). Contrary to adult DM, JDM is not 
associated with malignancy ( 11). 
 
Although a specific mechanism or agent is yet to be confirmed, immune reactions 
initiated by environmental factors in genetically susceptible individuals ( 12) and 
infectious triggers ( 13), have been suggested. Skeletal muscle and skin are primary 
targets in JDM, but with the systemic nature of the disease, other organs are affected as 
well. It is a vasculopathic disease where the small vessels are targets for inflammation 
and immune responses, both humoral and cellular ( 14). Many autoantibodies related to 
JDM have been identified. Some are shared with overlap syndromes and other 
autoimmune diseases (myositis-associated antibodies; MAA), for instance anti-Ku and 
anti-Ro 52. Others are highly specific to IIM (Myositis-specific antibodies; MSA). Anti-
Mi2, anti-signal recognition particle and anti-synthetases (e.g. anti-Jo-1) are examples 
that are well known. More recently, melanoma differentiation-associated gene 5 
(MDA5), transcriptional intermediary factor 1ɣ (TIF ɣ) and nuclear matrix protein 2 
(NXP2) have been described and added to the list of MSA’s ( 15; 16). Autoantibodies 
are seen in 40%-80% of JDM patients; a number rapidly increasing along with research 
in the area. Many of the MSA’s are associated with specific clinical subgroups of IIM 
and will probably play an important role in future classification – and treatment – of IIM. 
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Cardiac dysfunction and heart failure 
Systolic and diastolic heart failure 
Traditionally the term “heart failure” has been equivalent to the hearts’ inability to serve 
the organism with sufficient blood perfusion. A history of dyspnoe and fatigue and 
findings of pulmonary congestion, peripheral edema, neck vein distention, enlargement 
of the liver and a murmur or third heart sound on cardiac auscultation are among the 
commonest symptoms and physical signs. In many cases this is due to chamber 
dilatation and impaired contractile function of the heart, and on echocardiography, left 
ventricular (LV) ejection fraction (EF) is typically reduced ( 17). This is called systolic 
heart failure or Heart Failure with Reduced Ejection Fraction (HFREF).  
 
However, the last two decades, increasing awareness has been paid to those (up to 
50%) with clinical signs and symptoms of heart failure but with an intact contractility of 
the heart ( 18; 19). It is defined as diastolic heart failure or “Heart Failure with 
Preserved/Normal Ejection Fraction” (HFPEF/HFNEF) ( 20; 21). Other mechanisms are 
believed to be responsible than in those with systolic heart failure. In diastolic heart 
failure, the pattern of LV myocardial remodeling is characterized by normal chamber 
size and increased wall thickness. This results in impaired relaxation and increased 
stiffness of the myocardium. By some authors, impaired systolic and diastolic function 
are seen as two separate pathways to a failing heart ( 22). A strong argument for this is 
the lack of treatment effect in diastolic heart failure, by therapies developed for systolic 
heart failure. Still, no therapy has been proven effective in diastolic heart failure. 
However, other authors consider impaired systole and diastole as a continuum of 
cardiac damage since systolic heart failure is associated with impaired diastolic 
parameters, as well as abnormal longitudinal systolic function can be seen in patients 
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predominantly with diastolic heart failure ( 23).  
 
Cardiac dysfunction 
As mentioned above, heart failure is a clinical syndrome with characteristic symptoms 
and physical findings. The term cardiac dysfunction is less clearly defined, however; in 
literature it is most often based upon echocardiohgraphical measurement of EF, when 
assessing systolic function. In the SOLVD study, 4228 asymptomatic patients with LV 
dysfunction (EF ≤35%) were examined  ( 24). Other less strict definitions have been 
used ( 25), such as asymptomatic patients merely with a subnormal EF (≤54%), based 
on current guidelines ( 17). The prevalence of cardiac dysfunction reported varies (1.8 
to 12.5% in adult populations above 45 years) depending on the definition used ( 25; 26; 
27). As will be addressed in the Material and methods section, there are a number of 
other highly suitable indices to estimate systolic function such as strain, strain rate, MA 
plane movement, contrast ventriculography and cardiac MRI. In neither of these 
methods are there generally agreed cut-off values for systolic dysfunction. 
 
While diastolic heart failure has remained a somewhat controversial field, a consensus 
exists on the definition of diastolic dysfunction; this is based on transmitral Doppler 
inflow velocity and tissue Doppler of the mitral annulus (MA). According to current 
(2007) guidelines, the cut-off value for diastolic dysfunction is E/e’>15; when E/e’ is 
between 8 and 15, it is considered as possible diastolic dysfunction ( 21). Invasive 
measurements of LV filling pressure can also be used and, today considered less 
reliable, transmitral Doppler inflow velocity patterns (E/A-ratio). As in systole, absence 
of symptoms distinguishes dysfunction from heart failure.  
As expected, development of heart failure is much more common in patients with 
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cardiac dysfunction than in the normal population ( 27). In the SOLVD study, the 
incidence of heart failure and the rate of hospitalization were reduced in patients 
receiving enalapril treatment compared to the placebo group. Hence, cardiac 
dysfunction may be seen as asymptomatic state on the road to clinically overt heart 
failure. 
 
Cardiac dysfunction and inflammation 
The last two decades, strong links between inflammation and heart disease have been 
established ( 28; 29). In atherosclerosis, inflammation was noted through histologic 
observations ( 30). In the presence of endothelial dysfunction, adhesion molecules 
enable monocytes to enter the intima where they develop into macrophages. Together 
with T-cells, dendritic cells and mast cells, the activated macrophages (foam cells) 
contribute in the formation of atherosclerotic lesions through release of pro-inflammatory 
substances such as monocyte chemoattractant protein 1 (MCP-1, CCL2), interleukine 1 
(IL -1), IL-6, Il-18 and tumor necrosis factor α (TNF-α) ( 31) . In the progression of an 
atherosclerotic lesion, proliferation of smooth muscle cells, increased synthesis of 
collagen and accumulation of lipids, occurs. MCP-1, also produced by activated 
endothelial cells, plays an essential role in this development ( 32). The lipid cores of the 
foam cells increase in size and necrotize. The fibrous cap of the plaque is thinned, 
enhanced by oxidized LDL cholesterol, over-expression of matrix metalloproteinases 
(MMP) and TNF-α ( 28; 31). These final changes make the lesion increasingly 
vulnerable to plaque rupture and subsequently thrombosis and a cardiovascular event. 
Hence, inflammation is involved in all steps of atherosclerosis development. 
In the development of systolic cardiac failure, increased serum-levels of pro-
inflammatory cytokines are seen with increasing NYHA-class ( 29). The cytokines have 
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been shown to affect myocardium through a number of mechanisms. TNF-α is involved 
in systolic heart failure with negative inotropic effect and promotion of LV remodelling 
leading to hypertrophy and dilatation ( 33). MCP-1 and IL-6 also induce hypertrophy and 
myocardial fibrosis ( 29).  
 
The role of inflammation in diastolic heart failure is less studied. However, IL-6 ( 34), IL-
18 ( 35) and MCP-1 ( 36) are all associated with increased synthesis of collagen, 
fibrosis and myocardial stiffness in experimental models. Increased levels of TNF-α and 
IL-6 have been shown in patients with diastolic heart failure ( 37). In the post-myocardial 
infarction reparative, fibrotic process, the significance of MCP-1 and other cytokines are 
well documented ( 36). 
 
Cardiac dysfunction in rheumatic diseases, included idiopathic inflammatory myopathies  
There has been a growing attention to cardiac function in the field of rheumatic 
diseases. It is well documented that RA and SLE carries an increased mortality and 
morbidity from cardiac disease ( 38; 39; 40; 41; 42). In fact; RA patients die prematurely 
compared to the general population, probably largely as a result of increased 
cardiovascular death. They have a higher risk of sudden death and silent myocardial 
infarction and a worse outcome associated with heart failure ( 43). Similarly, patients 
with SLE have increased mortality and morbidity from premature ischemic heart 
disease, severe hypertension, heart failure and peri- and myocarditis ( 44). More 
recently, it has also been shown that patients with RA and SLE have diastolic 
dysfunction, compared to healthy controls ( 45; 46). It is likely that a high level of 
inflammation, present in all rheumatic diseases, plays a leading role in the pathogenesis 
in cardiac diseases in these patients as well ( 43). 
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In adult PM/DM, increased cardiac morbidity has during the last decades been 
recognised, although it has been considered mainly subclinical ( 47). However, 162 
Hungary patients with PM/DM were followed over median 5 years, 20 deaths occurred; 
of these 11 were due to cardiac causes: congestive cardiac failure, electromechanical 
conduction abnormalities and ischemic heart disease ( 48). This is similar to the pattern 
seen in RA and SLE. Recently in a large Swedish population based study, Zoller et al 
showed that there was a 4-fold increased risk of ischemic heart disease during the first 
year after hospitalisation from PM/DM – comparable to patients hospitalized from RA 
and SLE ( 49). Studies on the pathogenesis of cardiac involvement in PM have shown 
pathological ECG in 33 - 72%  ( 50; 51; 52; 53; 54). In two autopsy series from 1979 
and 1982, myocarditis was found in 6 of 20 and 4 of 16 patients with PM  ( 52; 55); only 
two children were included in each study and none of these had cardiac disease. 
Pericardial effusion has also been reported ( 56; 57), but no controlled studies have 
been carried out. The suggested underlying mechanisms of cardiac involvement in adult 
PM/DM are atherosclerosis in coronary arteries and perhaps small vessel, and 
myocarditis. 
 
To document cardiovascular events in JDM, a longer observational period is needed 
due to the young age of the patients; hence the data are scarcer. Interest has been paid 
to whether inflammation similar to what is seen in skeletal muscle also can occur in the 
heart. In theory, several factors can suggest cardial affection in JDM: Inflammation of 
skeletal muscle is a key feature of JDM; the inflammation has also been shown to be 
systemic in nature ( 14; 58). Given this knowledge it is not unlikely that inflammation can 
affect the myocardium in JDM patients. Publications from two large, but uncontrolled 
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cohorts of JDM patients have suggested that cardiovascular complications are rare  ( 5; 
59). Since early changes in |cardiac function can be subtle and subclinical, a control 
group is essential for detecting these. Up to now, no controlled study addressing cardiac 
function in JDM – or adult myositis- has been carried out, and the need for this has 
been raised by researchers in the field ( 47).  
 
Cytokines 
Classification of cytokines 
Cytokines are small signal molecules, produced by endothelial- immune- and muscle 
cells. They modulate, activate or inhibit immune responses and inflammatory reactions 
through a number of mechanisms. TNF-α can direct phagocytizing neutrophils to an 
inflamed area through up-regulation of adhesion molecules. Also MCP-1 is responsible 
for activation of macrophages and differentiation into phagocytizing cells. Furthermore, 
activation of B- and T- cells in the adaptive immune system is also cytokine driven, 
among others by IL-6 ( 60; 61).  
 
Classification of cytokines can be done on basis of structural homology. An example is 
CXC– and CC-chemokines; interferon inducible protein-10 (IP-10, CXC10) and MCP-1 
(CCL2) and eotaxin (CCL11) representing the two groups. These are structurally 
distinguished by one amino acid separating the two cysteins near their amino terminus. 
Another example is cytokines categorized from a three-dimensional structure, hence 
termed the four helix bundle families. 
 
There are many classifications on basis of functional properties and in the literature, this 
can be confusing. The term chemokine are used by cytokines promoting chemotaxis 
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between cells. Cytokines can be distinguished by those which are produced by Th1- 
lymphocytes (IFN-ɣ, IL-2 and IL-18) and those produced by Th2 - lymphocytes (IL-4, IL-
5, IL-10 and IL-13) ( 61; 62). The Th1- cytokines, along with TNF-α, IL-1, IL-6, IL-8, IL-
12 and, dominate in the acute phase of inflammation and are often termed pro-
inflammatory cytokines, while Th2 – cytokines and TGF-β are involved in the late, 
recovery phase and are therefore considered anti-inflammatory ( 63). Another 
commonly used distinction is type 1and type 2 interferon driven cytokines or signatures. 
This is referring to cytokines induced by type 1 interferons (IFN-α and IFN-β) as 
opposed to those induced by type 2 interferons (IFN-ɣ). Examples of cytokines known to 
be type 1 interferon-induced are IP-10, MCP-1 and IL-6. When the term signature is 
used, it most often refers to induction on a gene- and not protein level.  
 
Cytokines in JDM  
Cytokine-inducible receptors, enhancing inflammation have become central 
pharmacological targets in rheumatic diseases such as adult and juvenile idiopathic 
arthritis (JIA) ( 64; 65; 66). This has made the role of cytokines in the pathogenesis in 
myositis to an area of interest ( 67; 68; 69). Studies have been performed on gene 
expression level, both from muscular tissue and peripheral blood, and type 1 interferon 
signature is present and associated with disease activity in DM ( 70; 71). Increased 
plasma levels of IL-18 ( 72) and IL-15 ( 73) are reported in patients with DM/PM early in 
the disease course (first year and median 1 year, respectively). IL-15 also correlated 
with disease activity ( 73). In a controlled study on 37 DM and 19 JDM patients (median 
disease duration 2 years), several chemokines including MCP-1 and IP-10 were 
increased ( 74). However, the area is confusing; most studies performed on cytokines 
consist of mixed patients groups with PM, adult and juvenile DM, with variable disease 
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duration, in particular, few have long term follow-up. If controlled, the studies have been 
small. Despite numerous reports, yet no definite biomarker of JDM has been found and 
the knowledge about cytokine abundance remains limited. 
 
Cytokines, lipids and cardiac dysfunction in rheumatic diseases  
Increased atherosclerotic burden in RA ( 38) despite decreased or normal cholesterol 
levels ( 75; 76) has been raised as a paradox ( 77). This reduced threshold of 
unfavourable cholesterol levels could be due to cytokine-driven inflammation. 
Documentation is scarce; though, some studies suggest that pro-inflammatory cytokines 
are involved in development of cardiovascular complications in rheumatic diseases. A 
recent meta-analysis on rheumatoid arthritis (RA), showed that anti-TNF-α treatment 
reduced the risk of cardiovascular events  ( 78), and in 23 RA patients, IL-1 antagonists 
improved LV function  ( 79). Although studies have reported impaired glucose- and 
triglyceride metabolism in JDM ( 80), the impact of circulating lipid- and cytokine levels 
on cardiac function in patients with myositis has to our knowledge not been addressed.  
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AIMS OF THE STUDY 
Main aim 
To examine possible cardiac dysfunction in JDM patients, and investigate the 
association between patient characteristics, disease variables, cardiac function, lipids 
and specific cytokines. 
 
Specific aims 
o To assess left ventricular diastolic function and to investigate whether diastolic cardiac 
function is associated with patient characteristics and disease variables (paper I). 
o To assess left ventricular systolic function and to investigate whether cardiac function is 
associated with patient characteristics and disease variables (paper II). 
o To examine serum cytokine profile after medium to long disease duration, and to 
explore possible relationship with patient characteristics and disease variables (paper 
III). 
o To examine the relation between chemokines (eotaxin, MCP-1 and IP-10) lipid 
parameters and cardiac function, both in patients with active and inactive disease 
(paper IV).  
o To investigate possible early predictors of cardiac dysfunction and cytokines at follow-
up in patients (paper I+II+III). 
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MATERIAL AND METHODS - CONSIDERATIONS 
Study population and data collection 
A retrospective inception cohort of 66 patients with a probable or definitive diagnosis of 
JDM ( 9) was identified. In the medical records from January 1970 and June 2006, both 
manual and electronic searches were performed. Of 66 identified patients, 4 were 
deceased; the remaining 62 patients could all be tracked through the Norwegian 
Population Register and 59 (95%) agreed to participate in the study. Based on these 
data, the average annual incidence in Norway in the period was 2.9/mill.; this 
corresponds with literature from other countries ( 1; 2). Oslo University Hospital(OUS) 
has been a national referral centre for all JDM patients in Norway. Also, OUS is 
responsible for the care of children with rheumatic diseases in a region comprising 55% 
of the Norwegian population. Therefore, we believe that our study population represents 
by far most of the JDM patients in the country from this period.  
 
Because of large variation in age among our patients, one sex- and age-matched 
control per patient was randomly drawn from the National Population Register. This 
case-control design helps us to determine whether subclinical findings are specific to 
JDM or not. Exclusion criteria were mobility problems, other inflammatory rheumatic 
diseases, autoimmune diseases treated with immunosuppressive agents, heart- or lung 
disease, except for mild asthma. 
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Clinical examination - disease activity, organ damage and other clinical measures 
Clinical examination of all patients and matched controls was performed at OUS in the 
period September 2005 - May 2009 by Dr. Helga Sanner, this was defined as time of 
follow-up. A number of clinical measures were assessed: 
 
o Disease activity was measured by Disease Activity Score (DAS) for JDM  ( 81) (range 
0-20, 0 means no activity). DAS is composed of subscores for skin (DAS skin, 0-9) and 
muscle (DAS muscle, 0-11).  
o Cumulative organ damage was measured by Myositis Damage Index (MDI, range 0-
35/40) ( 58). MDI scoring does not distinguish between different causes of organ 
damage; a high score can also be secondary to disease activity, comorbidity or drug 
side-effects. 
o To assess physical function the Health Assessment Questionnaire (HAQ) ( 82) (patients 
aged ≥18 years, n=39) and the Child HAQ ( 83) (<18 years, n=20) were used.  
o Physical health was measured by the Short Form-36 (SF-36) physical component 
summary (PCS)  ( 84).  
o Inactive disease was defined by the proposed PRINTO (Paediatric Rheumatology 
International Trials Organization) criteria of 2012, at least 3 of the 4 following: manual 
muscle test (MMT-8) ≥78 (0-80) ( 85), physician global assessment of muscle activity 
(phyGloVAS) ≤0.2. Childhood Myositis Assessment Scale (CMAS) ≥48 and creatine 
kinase (CK) ≤150 ( 86).  
 
Retrospective disease data (onset, course, comorbidity) and DAS and MDI from the first 
year post-diagnosis were obtained from the medical records at OUS or, when 
necessary, from other hospitals. Disease onset was defined as time of the first muscle 
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or skin symptom clearly related to JDM and disease duration as the time from disease 
onset to the follow-up examination. History and use of medication was obtained both 
from study participants and by chart review. 
 
Echocardiography 
Background 
Since its beginning in the 1960’s, echocardiography as a method has developed and 
expanded dramatically. M-mode images of poor quality, reserved for a dedicated 
minority of enthusiasts were followed by Doppler and 2D images in the late 1970’s. 
Along with colour coded- and tissue Doppler, transoesophageal echocardiography was 
also developed. Digitalization and advanced software led to further improved quality of 
the imaging ( 87). Even during the last decade, researchers have paid interest to 
several new echocardiographic modalities, such as speckle tracking- ( 88), strain- and 
3D echocardiography ( 89). Although Magnetic Resonance Imaging of the heart (CMRI) 
has greatly improved and today contributes significantly, echocardiography is still by far 
the most important cardiac imaging technique in research as well as in clinical 
cardiology. Being affordable, robust, portable and fast, echocardiography has been the 
superior tool in most concerns. Still, echocardiography is faced by challenges such as 
standardization of measurements and limited acoustic window. Reduced visibility of LV 
walls makes reliable assessment impossible in some patients. Also, some techniques 
require highly specialized software or investigators. Another limitation in 
echocardiography can be high intra- and inter-observer variability. 
 
In our study, Dr. Ivar Sjaastad performed all echocardiographic examinations, utilizing a 
Vivid 7 ultrasound scanner (GE - Vingmed Ultrasound, Horten, Norway) ( 17; 90). The 
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data were analysed by the candidate TS, blinded to clinical information and to 
patient/control identity. We investigated inter- and intra-observer variability (paper II) 
and both were found to be acceptable.  
 
Systolic function – assessed by long axis strain  
We assessed systolic function by mitral annulus plane (MA) displacement, rather than 
by LV ejection fraction (EF). Although more generally used, EF has limitations due to 
difficulties in data acquisition when the acoustic window is poor, and assumptions of LV 
geometry ( 17; 91). MA displacement has been an index of systolic LV function since 
the early era of echocardiography ( 92; 93) and has recently regained interest. It has 
proven to be an accurate, easy and sensitive way of assessing systolic function and 
predicting cardiovascular risk ( 94). During systole, the LV apex is relatively stationary; 
hence the MA descent from diastole to systole reflects LV movement in the longitudinal 
axis and LV contractility. Long axis strain is the relative estimate of MA displacement, 
normalized to LV end diastolic length (the length of LV increases with body size) ( 95); it 
is calculated as MA displacement expressed as percentage of LV end-diastolic length:  
Calculation of long axis strain: 
Long axis strain = 100% x 
܍ܖ܌܌ܑ܉ܛܜܗܔܑ܋ۺ܄ܔ܍ܖ܏ܜܐି܍ܖ܌ܛܡܛܜܗܔܑ܋ۺ܄ܔ܍ܖ܏ܜܐ
܍ܖ܌܌ܑ܉ܛܜܗܔܑ܋ۺ܄ܔ܍ܖ܏ܜܐ  
 
Low long axis strain is associated with systolic dysfunction. In our cohort normalization 
of LV length was needed since our patients had large variation in age and body size. 
We assessed long axis strain in the four-chamber apical view by M-mode 
echocardiography, but it can be measured with TDI and MRI modalities ( 95) as well. 
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This method’s sensitivity to systolic dysfunction is probably higher than movement in the 
transverse/short axis (in M-mode, fraction shortening) and EF, and it is comparable to 
global longitudinal strain ( 96; 97). 
.  
Figure: Mitral annulus displacement, assessed in 4-chamber view by 2D echocardiography. 
 
Diastolic function – assessed by E/e’-ratio and e’ 
E/A-ratio (early- and late diastolic transmitral velocity of blood) <1, measured by 
conventional Doppler, has commonly been used as an indicator of impaired LV 
relaxation. In the progress of diastolic dysfunction, the phenomenon “pseudo-
normalisation” (E/A-ratio >1), occurs, which could make the diagnosis difficult. The last 
two decades it has become evident that TDI is more feasible than conventional Doppler 
to assess diastolic function ( 98). In our analyses, we used colour coded TDI to assess 
early diastolic tissue velocity (e’) with sample volumes averaged from four positions (in 
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the MA - lateral and septal position in four-chamber view and two correspondingly 
positions in two-chamber view). When pulsed wave TDI is used, generally accepted cut-
off’s are; diastolic dysfunction: E/e’ > 15 and possible diastolic dysfunction: 8<E/e’<15 ( 
18; 21). There are no generally accepted cut-off value value for colour coded TDI, but 
compared to pulsed wave, it is probably an underestimate of the pulsed wave TDI. 
Reports suggest that colour coded measures approximately 25% higher velocities than 
pulsed wave TDI ( 99); this corresponds well with our findings: in paper I, we defined 
“possible diastolic dysfunction” as E/e’ >mean +2SD of the matched control values, 
which was >9.5.In clinical settings however, e’ alone has proven to be equally reliable to 
E/e’ ( 100); being a single parameter, it is simpler and faster. Furthermore, e’ is reported 
to be less load dependent than E/e’ ( 98). Therefore, in paper II we utilized e’ alone as 
the parameter of diastolic dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: e’ assessed by tissue velocity in the mitral annulus, by colour coded TDI. 
e’ 
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ECG  
12-channel electrocardiography (ECG) was analysed (Paper I), blinded to clinical 
information and patient/control identity. Rhythm and ST segment were assessed, and 
PR-, corrected QT-interval (QTc) and QRS-duration were measured according to 
current practice ( 101). LV hypertrophy was assessed by Cornell voltage x QRS 
duration product which is probably more sensitive than the Sokalow criteria ( 102). 
Although no LV hypertrophy was detected in the patients by echocardiography, the 
patients did have a higher Cornell voltage x QRS duration product than the controls. 
The significance of this we have not discussed in depth, but it could suggest that this is 
a way to detect subtle changes in LV mass, not detectable on echocardiography. 
 
Laboratory analyses 
Analyses of cytokines - Luminex and ELISA technology 
26 cytokine were analysed by Luminex technology; a multiplex protein quantification 
method. Capture antibodies are coated to microspheres, not wells as in ELISA, in 
sandwich immunoassays. With Luminex technology it is possible to quantify up to 100 
different analytes simultaneously in a flow cytometer ( 61). This can be done with small 
sample volume, at a relatively low cost. The technology has been validated with good 
correlations against available ELISA kits ( 103). In our study, Luminex was used 
according to the manufacturer’s protocol with minor modifications, described in paper III. 
Optimizing the method to the sample material and design of the standard curves were 
performed prior to analyses, even though, challenges in the quantification exist. 
Cytokines may either be degraded by proteases or become undetectable due to 
antibodies and soluble receptors in the sample ( 61).Also, even stored at -70 degrees 
Celcius, freezing, storage and defreezing may impair the quality of the samples.  
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For paper III, IL-18, TGF-β1) and IFN-α were analysed with enzyme-linked 
immunosorbent assay (ELISA) technique. For IFN-α (a type 1 IFN) - analyses, ELISA 
has been a challenge due to sensitivity and specificity  ( 104). Typically, type 1 IFN 
signature (IFN-inducible gene- or protein expression in peripheral blood or affected 
tissue) has been easier show than increased type IFN-α itself  ( 71).  
There is no definite cut-off level for pathological levels of the CC chemokines eotaxin 
and MCP-1. As we did for the parameter of diastolic function E/e’, we therefore defined 
high eotaxin and high MCP-1 levels as serum concentration >mean +2SD of the values 
in the matched controls.  
 
Other serum analyses 
In patients and controls, venous samples including basic hematologic parameters, C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were collected. In JDM 
patients, creatine kinase (CK) and cardiac markers (Pro-brain natriuretic peptide (pro-
BNP) and Troponin-T in 37 patients) were analysed. 
 
In the preparation of Papers II and IV, lipid status was analysed. Since rheumatic 
diseases have lower cholesterol levels than the normal population and that cholesterol-
levels alone might be of limited value in the assessment of atherosclerotic risk in these 
patients ( 75; 105). Therefore, high density lipoprotein/low density lipoprotein (HDL/LDL) 
- and total cholesterol/HDL (TC/HDL) – ratios were of particular interest to detect an 
unfavourable lipid profile in the JDM patients. The TC/HDL-ratio, although less known, 
was in a large meta-analysis of prospective observational studies, mostly from western 
Europe or North America, consisting of almost 900,000 patients shown to be superior to 
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other lipid parameters in predicting ischemic heart disease ( 106). Hence, this was one 
of the parameters we focused on in paper IV. As our samples were drawn on non-
fasting subjects, we did not comment on triglyceride- or glucose levels in the patients. 
 
Statistics 
The statistics used are described in the papers. Differences between scorers (paper II) 
and between patients and matched controls, were tested by the paired sample t-test. 
Two tailed tests were used for all calculations except for comparisons where a priori 
patients, based on the literature were unlikely to have lower values than controls; e.g. 
pathological ECG (paper I), ESR and CRP (paper III).  
In the calculations of cytokines, five outliers were detected through Bonferroni 
corrections. These and their matched patients/controls were removed from the data set 
therefore results from the remaining 54 patients/control pairs are presented in paper III 
and IV. 
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SUMMARY OF RESULTS  
Paper I: Cardiac dysfunction in juvenile dermatomyositis: a case control study. 
o E/e’ was elevated (>9.5) in 13 (22%) patients but in none of the controls (p<0.001), 
suggesting a subclinical LV diastolic dysfunction in JDM.  
o Ten patients presented with pathological ECG compared to 4 controls (p=0.054). 6 of 
13 patients with elevated E/e’ vs. 4 of 44 with normal E/e’, had pathological ECG 
(p=0.002);  
o Previous or current hypertension was found in 12 (20%) patients vs. 0 controls 
(p<0.001). Systolic BP was higher in patients with elevated E/e’ than in those with 
normal E/e’ (132mmHg ±24 vs. 112mmHg ±18, p=0.012). 
o Diastolic function (E/e’) correlated with cumulative organ damage (MDI) assessed at 
follow-up (rsp=0.41, p=0.001) and disease activity (DAS) at 1 year post-diagnosis 
(rsp=0.56, p<0.001). DAS total 1 year post-diagnosis, also predicted pathological E/e’ 
after controlling for age and gender (standardized β=0.49, R2=36%; p<0.001). 
o During disease course, 7 (12%) JDM patients developed pericarditis. 
 
 
Paper II: In juvenile dermatomyositis cardiac systolic dysfunction is present after 
long-term follow-up, and is predicted by sustained early skin activity. 
o Systolic function (long axis strain) was impaired in patients compared to controls (16.6% 
(2.5) versus 17.7% (2.0), p=0.001). Between patients with active and inactive disease, 
no difference was seen.  
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o Disease duration correlated with systolic and diastolic (e’) function (rsp= -0.50 and rsp= -
0.73, p’s<0.001) and so did cumulative organ damage (MDI) 1 year post-diagnosis 
(rsp=-0.36 and rsp=-0.46) and MDI at follow-up (rsp=-0.33 and rsp=-0.60), all p’s<0.01.  
o High early disease activity score (DAS) 1 year post-diagnosis in skin, but not in muscle, 
predicted systolic (standardized β=-0.28, p=0.01, R2=48%) and diastolic dysfunction 
(β=-0.36, p<0.001, R2=72%) at follow-up.  
o A common pathway to two different cardiac manifestations may be present, perhaps 
with similar pathogenesis as skin affection. 
 
 
Paper III: Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis 
median 16.8 years after disease onset; associations with disease activity, 
duration and organ damage. 
o Of 26 cytokines analysed by Luminex, only eotaxin, MCP-1 and IP-10 were elevated in 
patients compared to controls (31.5%, 37.2% and 43.2%, p’s<0.05). IL-8, IL-13, TNF-α 
and IL-6, were numerically higher in the patients; p’s=0.06 - 0.08. 
o Levels of eotaxin and MCP-1 correlated with disease duration (rsp=0.47 and rsp=0.64, 
p’s<0.001).  
o In a linear regression analysis, at follow-up MCP-1 was associated with cumulative 
organ damage (MDI) (standardized β=0.43, p=0.002) after adjusting for disease 
duration and gender. High MDI 1-year post-diagnosis predicted high levels of eotaxin 
and MCP-1 at follow-up (standardized β=0.24 and 0.29, p’s<0.05).  
o The findings highlight a role of eotaxin and MCP-1, possibly involved in a sustained 
inflammation in JDM. 
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Paper IV: In active state of juvenile dermatomyositis: elevated eotaxin and MCP-1, 
and cholesterol level in the upper normal range are associated with cardiac 
dysfunction.  
o In patients, but not in controls, eotaxin and MCP-1 correlated with systolic (long axis 
strain) and diastolic function (e’), particularly in those with active disease (systolic 
function, rsp=-0.74 and rsp=-0.60; diastolic function, rsp=-0.69 and rsp=-0.80).  
o Total cholesterol level was lower in patients than controls (4.19 (0.82) vs. 4.60 (0.87) 
mmol/L p<0.01).  
o However, total cholesterol levels in the upper normal range were associated with 
systolic and diastolic dysfunction (rsp=-0.56, p<0.01 and rsp=-0.64, p<0.001) and with 
high eotaxin and MCP-1 (rsp=0.56, rsp=0.50, p’s<0.01) in patients with active disease, 
but not in those with inactive disease or in controls (rsp’s <±0.2).  
o It is possible that eotaxin and MCP-1 enhance susceptibility to cardiac dysfunction in 
patients with active disease through sustained inflammation. 
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DISCUSSION 
Systolic and diastolic dysfunction in JDM 
The main findings in paper I and II is the diastolic and systolic dysfunction seen in JDM 
patients examined after medium to long term follow-up. This has never been shown 
earlier in controlled studies neither in JDM nor, to our knowledge, in adult PM/DM. 13 
patients fulfilled our criteria for possible diastolic dysfunction, however, the 
echocardiographic signs of cardiac dysfunction were subclinical and mainly detectable 
on a group level when compared with healthy controls. Our study design with sex- and 
age-matched controls has therefore been crucial for detection of these results.  
In literature on diastolic dysfunction, E/e’ has been more extensively documented than 
e’ alone ( 21). Recently e’ alone has been advocated as an easy and equally reliable 
parameter on diastolic dysfunction ( 100). In our analyses, we found E/e’ and e’ alone 
to be equally impaired in JDM patients compared to the controls (paper I). E/e’ and e’ 
were both associated with blood pressure, with stronger correlations for e.’  
 
JDM patients had impaired long axis strain compared to the controls whereas no 
difference was seen in EF. In the analyses of systolic function we found long axis 
strain to be a more suitable parameter than EF: long-axis strain was successfully 
assessed in all, whereas EF was not obtainable due to acquisition challenges in 13 of 
118 individuals. As already discussed, EF is a well established index of systolic 
function but has several limitations. In our analyses, EF correlated neither with 
diastolic function (e’ or E/e), nor with blood pressure, whereas long axis strain 
correlated well with both. Patients with possible diastolic function had impaired long 
axis strain compared to the patients with normal diastolic function (14.7% (3.1) vs. 
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17.2% (2.1), p=0.001, unpublished data). This may suggest that diastolic and systolic 
dysfunction result from the same pathogenetic processes. 
 
Cardiac dysfunction: a long term complication of JDM 
What is the significance of a subclinical cardiac dysfunction in JDM patients? Notably, 
only one of our patients had clinically detectable heart disease. In the acute phase of 
JDM, cardiac affection such as myocarditis has been reported ( 52; 55), but is 
uncommon. In our study, long disease duration was associated with pathological ECG 
and impaired parameters of systolic and diastolic function, particularly long axis strain 
and e’. Hence, we believe that cardiac dysfunction is a long term complication in JDM. 
However, some studies have suggested that cardiac affection in JDM is rare  ( 5). But 
since JDM is a disease of childhood and adolescence and our patients had a median 
age of 21.5 years (range 6.7–55.4), clinically overt cardiac disease would hardly be 
expected until later in life. In adult PM/DM increased risk of cardiovascular death or 
clinically overt heart disease have been documented ( 48; 49). In these patients, 
cardiac end points are easier to show probably because this is an adult population. 
JDM share many disease mechanisms with adult PM/DM. Thus, it is likely that JDM 
patients, similar to PM/DM- and patients with other rheumatic diseases, are at risk of 
premature cardiac disease. This however, remains to be shown, and long term 
observational studies are needed to show hard cardiovascular end points. In our 
cohort, the patients that got their diagnosis before 1990 were treated less aggressively 
( 4). This may also have contributed to the correlation seen between disease duration 
and cardiac function. 
A history of pericarditis was found in a remarkable high number of the patients (7 of 
59), 5 of these within 1-2 years after JDM diagnosis. However, pericarditis did not 
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correlate with cardiac function, ECG-findings or disease parameters. This can suggest 
that the underlying mechanisms of pericarditis are different from those responsible for 
cardiac dysfunction in JDM.  
 
Cardiac dysfunction; associations with disease activity and organ damage 
Tools assessing disease activity and organ damage is crucial in the care of patients 
with myositis. JDM is a systemic disease ( 4; 14) and organ damage is scored 
according to severity and number of additional organ systems involved. Disease 
activity by DAS (used in the present thesis) on the other hand, is evaluated through 
the activity of skin- and muscle disease. We used MDI and DAS among several tools 
to assess organ damage and disease activity in myositis ( 58).  
 
Both long axis strain, e’ and E/e’ were associated with disease activity and organ 
damage, e’ stronger than E/e’. For disease activity the associations were present only 
for DAS 1 year post-diagnosis, not DAS follow-up, and more so for DAS skin than DAS 
muscle. The poor correlation with DAS muscle is interesting; one of the reasons why 
we hypothesized cardiac dysfunction in JDM was a presumed generalized affection of 
muscle and similarity between cardial and skeletal muscle tissue. We assumed that 
what caused inflammation in skeletal muscle, could affect cardiac muscle as well. 
Instead, we found a stronger association between DAS skin and cardiac function; high 
DAS skin 1 year post-diagnosis also predicted both systolic and diastolic dysfunction. 
This supports a disease mechanism in the myocardium similar to that occurring in 
skin, rather than in skeletal muscle. JDM is a vasculopathy affecting small vessels; this 
is visualized by nailfold capillaroscopy (NFC). Studies have reported associations 
between pathological NFC and skin- but not muscle affection ( 107; 108). This 
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implicates that the small vessel disease is more prominent in skin than in muscle. A 
similar small vessel vasculopathy might be present in myocardium as well. 
 
The PRINTO criteria for clinically inactive disease were published in 2012. We were 
not able to detect any difference between the inactive and the active patients in 
respect of cardiac parameters. This observation goes well with the lack of correlation 
between cardiac parameters and DAS at follow-up. Whereas high activity in skin early 
in the disease (DAS 1 year post-diagnosis) is associated with cardiac dysfunction, 
disease activity at a later stage of the disease (DAS at follow-up and active state JDM) 
does not seem to have an impact on cardiac function. It seems likely that high early 
disease activity induces permanent organ damage, detectable at a later stage. 
 
Both e’ and long axis strain were associated with cumulative organ damage at 1 year 
post-diagnosis and at follow-up; e’ more so with MDI at follow-up. The cardiovascular 
components in MDI include: hypertension, LV dysfunction/cardiomyopathy, myocardial 
infarction and ischemic heart disease (IMACS form 08, Myositis damage index, 2001). 
It should be underlined that the MDI scoring of the patients were done prior to our 
echocardiographic analyses; our cardiac analyses are not included in the MDI scoring. 
Since LV dysfunction is a MDI criterion, the correlation between our echocardiographic 
findings and cumulative organ damage fits well with this.  
 
Significance of elevated levels of CC chemokines in JDM 
As mentioned in the Introduction, a number of studies have addressed interferon 
signatures and cytokine activity/concentration, at gene or protein levels in JDM ( 69; 
73; 74). Most of the studies have examined patients at a medium term follow-up with 
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disease duration 6 years or less. 
 
We examined 29 cytokines median 17 years after disease onset and found MCP-1, 
eotaxin and IP-10 to be significantly increased in JDM patients. All the other cytokines 
analysed (except IFN-α) were numerically elevated in the patients compared to 
controls. This tendency is remarkable keeping in mind that cytokines were analysed at 
a time point where half of the patients had inactive disease with few or no symptoms. 
Since only weak correlations were seen between MCP-1 and eotaxin and age in the 
controls, the correlations between MCP-1 and eotaxin and disease duration in the 
patients were not a result from aging per se. It is noteworthy that none of the cytokines 
showed a negative correlation with disease duration as one perhaps might expect, 
examined years after the acute phase of the disease. These findings suggest a 
sustained inflammation in JDM, ongoing also during the phase of remission. Even the 
data give indications; it is not obvious how this affects the clinical course of the 
disease.  
 
At follow-up, MCP-1 and eotaxin correlated with cumulative organ damage (MDI). 
However, at this time point there were no correlations with disease activity (DAS); 
neither were there any differences in cytokine levels between patients when stratified 
to active and inactive state of the disease. Eotaxin and MCP-1 correlated weakly with 
both organ damage and disease activity, only in skin, not muscle, assessed early (1 
year post-diagnosis) in the disease course. Similarly, for cardiac function, we also saw 
the strongest associations present were with DAS skin 1 year post-diagnosis and with 
MDI at follow-up. It seems like disease processes are initiated early, perhaps causing 
a sustained inflammation (elevation of MCP1 and eotaxin), resulting in myocardial 
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damage late in the disease course. This may, as already suggested, be caused by 
small vessel vasculitis in skin and myocardium. 
 
Why should sustained inflammation manifest as late organ damage but not increased 
disease activity? If JDM “burns out”, it is hard to explain the observation that the pro 
inflammatory chemokines MCP-1 and eotaxin increase along with increased disease 
duration. Eotaxin has been associated with fibrosis in different tissues ( 109; 110). It is 
possible that eotaxin induces similar tissue fibrosis in the heart, either by recruiting 
granulocytes that release pro-fibrotic substances, or by itself. None of our parameters 
were associated with DAS follow-up; it could be that this tool is suboptimal in 
assessing certain kinds of late disease activity. From our perspective, it is reasonable 
to assume an ongoing process of disease activity if a patient has elevated level of 
cytokines and cardiac dysfunction. Therefore, a low DAS may not be representative for 
all kinds of late disease activity in JDM.  
 
Five cytokines were numerically elevated in JDM patients with borderline significant p-
values (p<0.08). These were IL-13, IL-8, IL-1Ra and notably, IL-6 and TNF- α: the two 
best documented targets of receptor blockade treatment in rheumatic diseases ( 64; 
65). We may have been underpowered to detect an increase in these cytokines.  
In year 2000, in an often sited paper, Pachman et al. reported that presence of the 
TNF-α 308A allele and increased production of TNF-α, was associated with a severe 
disease course ( 69). Another study showed increased type1 interferon activity in adult 
and juvenile DM; type 1 inducible proteins (including IL-6, IP-10 and MCP-1) were 
associated with disease activity ( 74). In our study, eotaxin and MCP-1 were the only 
cytokines that correlated with early disease activity, disease duration and organ 
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damage; none of the other cytokines did. Still, we are not able establish causality: 
eotaxin and MCP-1 might be responsible for impaired disease parameters through 
inflammation, but they might also be driven by other disease mechanisms. 
 
In paper II, we have speculated in a biphasic cytokine response where an initial peak 
in cytokine levels is followed by a decrease and then a steady long term raise in the 
remission phase. Large, prospective studies are needed to show this. We are not 
aware of studies on cytokine with repetitive sample collections from the different 
phases (acute and chronic) of JDM. Due to the inflammatory nature of the disease, a 
general activation of cytokines in the period around disease onset and in the early 
phase of the disease seems likely. This was shown in a Swedish population based 
study where healthy persons who shortly after developed RA had increased levels of a 
number of cytokines (including MCP-1, eotaxin, TNF-α, IL-6 but not IP-10) compared 
to those who did not develop RA ( 111). Due to the rarity of the disease, such changes 
would be hard to show in JDM.  
 
MCP-1 and eotaxin and cardiac function  
Studies done on cytokines and cardiac affection in rheumatic diseases are limited; in 
particular, we have not found any studies addressing this in myositis. In the literature, 
MCP-1 is perhaps the cytokine strongest associated with myocardial inflammation, 
atherosclerosis development and fibrosis; it also predicts cardiovascular events in 
patients with acute coronary syndrome ( 32; 36). Eotaxin is closely related to MCP-1 
and also linked to cardiac fibrosis ( 112). 
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In our data, MCP-1 and eotaxin were associated with disease parameters (paper III) 
and with cardiac function (paper IV). Due to this concurrence, the findings in paper II are 
not surprising; in patients but not controls, both eotaxin and MCP-1 correlate with 
systolic and diastolic function. It appears that eotaxin is stronger linked to systolic 
function whereas MCP-1 to diastolic function: patients with high eotaxin tended to have 
systolic impairment and patients with high MCP-1 had diastolic impairment. For the 
other 27 cytokines analysed, including IP-10, TNF-α and IL 6; no associations with 
cardiac function were seen. This leaves MCP-1 and eotaxin in a unique position and is 
a main finding in our study: unlike all other cytokines, eotaxin and MCP-1 were elevated 
in JDM patients and correlated with disease parameters as well as cardiac function. 
The role of eotaxin and MCP-1 in the cardiac affection in JDM seems solid: there are 
associations with systolic and diastolic dysfunction and also with parameters of 
dyslipidemia and blood pressure. For MCP-1, this fits nicely with the overwhelming 
amount of documentation connecting MCP-1 to cardiac disease ( 29; 113; 32; 114; 
115). Eotaxin is far less studied; but with 49% homology, 64% shared protein structure ( 
116) and in our data, intercorrelation with MCP-1, it would not be surprising if eotaxin in 
the future will prove to be another important chemokine in the pathogenesis of cardiac 
diseases.  
 
Similar to that discussed for disease parameters; whether there is causality in the 
correlation between the CC chemokines and cardiac dysfunction, is yet to be answered. 
We have investigated the patients at a single time point (though different time from 
patient to patient) of the disease course. It could well be that the CC chemokines are 
responsible for changes in cardiac function that are uncovered in the study and that 
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eotaxin and MCP-1 could be useful biomarkers for these. On the other hand, it could 
also be that eotaxin and MCP-1 are stimulated and increased by other unknown 
disease mechanisms. However, experimental studies with mouse models has shown 
reduced myocarditis both through CCR2 –receptor blockade (to which MCP-1 is a 
natural agonist) and in CCR2 knock out mice ( 117), while increased heart failure 
through myocarditis was seen in other mouse models with increased MCP-1 gen 
expression ( 118). Even if there is a way from mice to men with JDM, these results 
support that MCP-1 has a role in the development of cardiac dysfunction seen in JDM.  
 
Unfavorable lipid profile in JDM  
The association between lipid metabolism and cardiac dysfunction in rheumatic 
diseases appears to be complex ( 105). In RA, increased susceptibility to 
atherosclerosis is present despite cholesterol levels in the normal range ( 38; 49; 75). 
Cardiovascular risk stratification of patients with rheumatic diseases must take this into 
consideration. JDM patients had lower cholesterol levels, but higher TC/HDL-ratio than 
the controls. Also, lipodystrophy was seen in 19% of the JDM patients; these indicate an 
unfavourable lipid-profile. As in other rheumatic and autoimmune diseases, increased 
atherosclerotic burden is present in adult DM ( 49); in JDM, this is not yet shown. Most 
of JDM patients in our cohort are probably too young to have developed detectable 
atherosclerotic heart disease. The cardiac dysfunction observed in our study,might 
reflect an early stage in the atherosclerotic development or the atherosclerosis may 
already be present as small vessel disease. It is possible that JDM patients are at risk of 
developing premature atherosclerotic heart disease. 
 
In RA it has been shown that impaired cardiovascular parameters are associated with 
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active state of the disease. 82 Norwegian RA patients had higher pro-BNP and higher 
systolic blood pressure but lower cholesterol levels than 31 patients with inactive 
disease and 86 controls ( 76). We did not detect any differences in cytokine-levels, lipid-
levels or cardiac function between those with inactive and those with active disease, but 
the following observations are interesting: correlations between the CC chemokines 
eotaxin and MCP-1, and cardiac function, blood pressure, lipodystrophy and lipid 
parameters (total cholesterol and TC/HDL-ratio) were only present in patients with 
active, not inactive disease and not in controls. Similarly, lipid parameters (total 
cholesterol and TC/HDL-ratio) only correlated with cardiac function, blood pressure and 
lipodystrophy in patients with active, not inactive disease and not in controls. In those 
with active disease state, eotaxin and MCP-1 may increase vulnerability to cholesterol 
and lowered the threshold of harmful cholesterol levels. These patients might be more 
sensitive to pathological myocardial remodelling due to chronic inflammation. Seemingly 
at risk of cardiovascular complications, it is possible that those with active state of JDM 
would benefit from more aggressive prophylactic treatment. On the other hand, one can 
not rule out that MCP-1 and eotaxin are confounding factors for other processes 
responsible. 
 
It is somewhat intriguing: three of the PRINTO criteria are based upon disease activity 
in muscle (MMT-8, CMAS and CK) ( 86) whereas few of the parameters in our analyses 
were associated with disease activity in muscle. Yet, the PRINTO criteria seem suitable 
in stratifying JDM patients into groups with distinct cardiovascular and inflammatory 
profiles. These indications must be interpreted carefully though, especially since there 
were no differences in cytokine- or lipid-levels or cardiac function on a group level, 
between those with inactive and those with active disease. 
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Prospective follow-up studies could clarify whether targeted receptor blockers of the 
chemokines and use of statins can prevent cardiovascular complications and whether 
PRINTO criteria are useful in cardiovascular risk stratification in JDM. 
 
Limitations and future plans 
A retrospective inception cohort like ours is suitable when assessing long term effects of 
the disease. Our median follow-up time is 16.8 years, with a large span of disease 
duration (2.0-38.1 years). However, the retrospective chart review on which some of the 
scores (early disease activity -DAS and MDI) are based upon, remains a possible 
source of error as it relies entirely on the quality of the documentation. The retrospective 
scoring and application of diagnostic criteria might have been based on incomplete 
charts, and hence represents a limitation of the study.  
 
Also, it could be criticized that our study is only a glimpse into long disease process. At 
present, we are reexamining the patients in our JDM cohort, approximately 8 years after 
their first visit. This will give us a unique possibility to see development of disease 
parameters, cytokine profile and cardiac function in each and one patient over time. 
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CONCLUSIONS 
We have found systolic and diastolic dysfunction as long term consequences in the 
disease of JDM; both with associations to long disease duration, high initial disease 
activity in skin and high cumulative organ damage later in the disease course. By 
echocardiography, long axis strain and e’ proved to be suitable indices of systolic and 
diastolic function. 
 
The CC chemokines eotaxin and MCP-1 were increased in the JDM patients. High 
serum levels were associated with long disease duration, high cumulative organ 
damage and cardiac dysfunction. 
 
Low cholesterol levels, yet an unfavorable lipid profile, were seen in JDM. Only present 
in those with active disease, associations between cholesterol in the upper normal 
range and increased eotaxin, increased MCP-1 and cardiac dysfunction, may indicate 
increased vulnerability to atherosclerotic disease in those with in active state of JDM. 
 
High disease activity in skin 1 year post-diagnosis predicted both systolic and diastolic 
dysfunction, whereas high cumulative organ damage 1 year post-diagnosis predicted 
high eotaxin and MCP-1. 
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Abstract
Objective: To compare cytokine profiles in patients with juvenile dermatomyositis (JDM) after medium to long-term follow-
up with matched controls, and to examine associations between cytokine levels and disease activity, disease duration and
organ damage.
Methods: Fifty-four JDM patients were examined median 16.8 years (2–38) after disease onset (follow-up) and compared
with 54 sex- and age-matched controls. Cytokine concentrations in serum were quantified by Luminex technology. In
patients, disease activity score (DAS), myositis damage index (MDI) and other disease parameters were collected by chart
review (early parameters) and clinical examination (follow-up).
Results: Serum levels of eotaxin, monocyte chemoattractant protein-1 (MCP-1) and interferon-inducible protein 10 (IP-10)
were elevated in JDM patients compared to controls (31.5%, 37.2% and 43.2% respectively, all p,0.05). Patients with active
(n = 28), but not inactive disease (n = 26) had a higher level of MCP-1 than their respective controls. Levels of eotaxin and
MCP-1 correlated with disease duration (r = 0.47 and r = 0.64, both p,0.001) and age in patients, but not with age in
controls. At follow-up, MDI was associated with MCP-1(standardized b= 0.43, p = 0.002) after adjusting for disease duration
and gender. High MDI 1 year post-diagnosis predicted high levels of eotaxin and MCP-1 at follow-up (standardized b= 0.24
and 0.29, both p,0.05) after adjusting for disease duration and gender.
Conclusion: Patients with JDM had higher eotaxin, MCP-1 and IP-10 than controls. High eotaxin and MCP-1 at follow-up was
predicted by early disease parameters, and MCP-1 was associated with organ damage at follow-up, highlighting a role of
these chemokines in JDM.
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Introduction
Juvenile dermatomyositis (JDM) is a systemic autoimmune
vasculopathy of childhood, involving proximal muscle weakness
and characteristic skin lesions. While the mortality rate has
decreased (now ,3%) [1], still 30–61% of patients have signs of
sustained disease activity and 60–90% develop organ damage 7.2–
16.8 years after disease onset [1–3]. Thus new therapeutic targets
could improve patient care; however, the pathogenesis of JDM is
not fully understood.
Cytokines are small signal molecules, produced by endothelial-
immune- and muscle cells. They mediate and regulate innate and
adaptive immune responses and inflammatory reactions through a
number of mechanisms including recruitment and activation of
leukocytes [4]. During the last decade, the role of cytokines and
chemokines (chemotactic cytokines) in the pathogenesis in myositis
has been an area of interest [5,6]. However, most studies
performed on cytokines consist of mixed patients groups with
polymyositis (PM), adult dermatomyositis (DM) and juvenile DM
and if controlled, the studies are small. Increased plasma levels of
interleukine 18 (IL-18) [7] and IL-15 [8] are reported in patients
with DM/PM early in the disease course (first year and median 1
year, respectively). IL-15 was also shown to correlate with disease
activity [8]. In a controlled study on 37 DM and 19 JDM patients
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(median disease duration 2 years), several chemokines including
monocyte attractant protein-1 (MCP-1) and interferon-inducible
protein 10 (IP-10) were increased [9]. Recently, criteria for
clinically inactive disease state in JDM were proposed by the
Paediatric Rheumatology International Trials Organization
(PRINTO) [10]; however it is not clear whether disease state is
associated with a specific signature of cytokines or inflammatory
parameters.
Knowledge about cytokine abundance in myositis, in particular
JDM, is limited. Specifically there is lack of studies with long-term
follow up. Our sex- and age-matched patient-control pairs [11,12]
provide a unique opportunity to compare the cytokine profile in
JDM patients after medium to long-term follow-up and to explore
how cytokine levels correlate with measures of disease activity and
damage at follow-up and at 1 year post-diagnosis.
Materials and Methods
Patients and controls
Inclusion criteria were a probable or definitive diagnosis of DM
according to the Bohan and Peter criteria [13], disease onset
before 18 years, minimum 24 months disease duration and age$6
years at inclusion. We identified a retrospective inception cohort of
66 JDM patients diagnosed between January 1970 and June 2006
in Norway, previously described in detail [2,14,15]. Four of the
patients were deceased; the remaining 62 could all be tracked
through the Norwegian population register, and 59 (95%)
participated in the study.
Sex- and age-matched controls were randomly drawn from the
National Population Register. Exclusion criteria in the controls
were: mobility problems, inflammatory rheumatic disease, other
autoimmune conditions treated with immunosuppressive agents,
and heart or lung disease (except for mild asthma). After cytokine
analyses, statistical calculations to detect outliers were performed
and 5 pairs were excluded (see statistical analysis). The data
presented are based on the remaining 54 patients and 54 controls.
Ethics statement
Written informed consent was obtained from all patients and
controls (and their parents if aged below 16 years), according to
the Declaration of Helsinki. The study was approved by the South-
Eastern Regional Ethics Committee for Medical Research.
Data collection and clinical measures
At Oslo University Hospital from September 2005 to May
2009, a single physician (HS) performed clinical examination of all
patients, median 16.8 years (range 2–38 years) after disease onset
(follow-up), and matched controls. In patients, disease activity was
assessed by Disease Activity Score (DAS) for JDM [16] (range 0–
20, 0= no activity), which consists of DAS skin (0–9) and DAS
muscle (0–11). Cumulative organ damage was measured by
Myositis Damage Index (MDI, range 0–35/40) [17]. In addition,
retrospective scoring of DAS and MDI from the first year post-
diagnosis were performed, based on chart review [2]. From the
criteria proposed by PRINTO (2012), inactive disease was defined
as at least 3 of the following 4: manual muscle test (MMT-8) $78
(0–80), physician global assessment of muscle activity (phyGlo-
VAS) #0.2, Childhood Myositis Assessment Scale (CMAS) $48
and creatine kinase (CK) #150 [10,18]. JDM patients with
inactive disease are referred to as JDM-inactive and the remaining
patients are called JDM-active. Physical health was measured by
the Short Form-36 (SF-36) physical component summary score
(PCS) [19]. The Health Assessment Questionnaire (HAQ) [20]
and the Childhood HAQ [21] were used to measure physical
function in patients aged $18 years (n = 35) and ,18 years
(n = 19), respectively. At time of follow-up, none of the study
participants had clinical signs of infection. Disease onset was
defined as the time of the first muscle or skin symptom clearly
related to JDM (by chart review) and disease duration as the time
from disease onset to follow-up examination. History of medica-
tion was obtained from study cases and by chart review.
Laboratory analyses
At follow-up examination, venous blood samples were collected
and serum concentrations of 29 cytokines analysed. IL-1b, IL-1
receptor antagonist (Ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8
(CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, basic fibroblast
growth factor (bFGF), granulocyte-colony-stimulating factor (G-
CSF), granulocyte-macrophage colony-stimulating factor (GM-
CSF), interferon c (IFN-c), IP-10 (CXCL10), MCP-1 (CCL2),
macrophage inflammatory protein 1a (MIP-1a) (CCL3), MIP-1b
(CCL4), eotaxin (CCL11), platelet-derived growth factor bb
(PDGF), TNF-a, and vascular endothelial growth factor (VEGF)
were quantified using Bio-Plex protein array systems (Bio-Rad,
Hercules, CA), based on xMAP technology (Luminex, Austin,
TX). The Luminex analyses were performed according to
manufacturer’s protocol, with minor modifications [22], including
selection of high-sensitivity standard curve to optimize measure-
ments of non-septic concentrations of cytokines. However, the
high-sensitivity standard curve yielded physiological concentra-
tions of Regulated upon Activation, Normal T-cell Expressed, and
Secreted (RANTES/CCL5) above detection limit. RANTES was
therefore excluded for further analyses. An intra-assay variation
with a coefficient of variation (CV) of 7.4960.81 was calculated
based on measurements of standards. To diminish the effect of the
inter-assay variation, all samples were analyzed in a randomized
fashion. Three of the 29 cytokines, IFN- a, IL-18 and transforming
growth factor b1 (TGF-b1), were analysed with enzyme-linked
immunosorbent assay (ELISA) technique.
Along with cytokine analyses, Th1/Th2 cell balance (ratio
between CD4+ Th1 helper cells that produce IFN-c and IL-2 and
CD4+ Th2 helper cells that produce IL-4, IL-5, IL-6, IL-10 and
IL-13) was evaluated by calculating the ratio of IFN-c/IL-4 [23].
Erythrocyte sedimentation rates (ESR) were assessed and high-
sensitive serum concentration of C-reactive protein (CRP)
analysed.
Statistical analysis
Differences between patients and matched controls were tested
by the paired sample t-test for normally distributed continuous
variables. Two tailed tests were used for all calculations except for
comparisons where a priori patients, based on the literature were
likely not to have lower values than controls (e.g. ESR and CRP).
Bonferroni correction was performed when appropriate. Correla-
tions were determined by Spearman correlation coefficient (r).
Association between eotaxin and MCP-1 (dependent variables)
and MDI, DAS skin and DAS muscle measured 1 year post-
diagnosis and at follow-up (independent variables) were tested in
multivariate linear regression models with forward deletion of the
variables after controlling for age and gender. Age was not
included in the linear regression model due to high intercorrela-
tion (r = 0.9) with disease duration. p value ,0.05 was considered
significant. SPSS version 20.0 (SPSS, Chicago, Il) was used for
statistical analyses.
To detect outlying individuals, we calculated the mean cytokine
levels for all groups and found the Mahalanobis distance from the
cytokine level of each individual to its respective group mean.
Bonferroni corrected p values were obtained based on an
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approximation of the Mahalanobis distance to a chi square
distribution with the number of cytokines as degrees of freedom.
One patient and four controls had samples with a p value ,0.001
and were therefore considered to be outliers. These five and their
matched control or patient were removed from the data set before
the remaining statistical analyses, hence data from 54 pairs were
analyzed and presented.
Results
Characteristics and serum cytokine levels in JDM patients
and controls
Characteristics of the 54 JDM patients and 54 sex- and age-
matched controls are shown in Table 1. Eotaxin-, MCP-1- and IP-
10-levels were higher in patients than in controls (31.5%, 37.2%
and 43.2% respectively, all p,0.05, Table 2). No differences
between patients and controls in levels of the other 26 cytokines,
Th1/Th2 ratio (Table 2), CRP or ESR were found (Table 1).
Cytokines and inflammatory parameters in JDM-active vs
JDM-inactive and in JDM-active and JDM-inactive vs
controls
According to PRINTO criteria, 26 (48%) of the patients had
inactive disease. No differences were found between JDM-active
and JDM-inactive in ESR (8.5 (6.1) vs 5.9 (4.7) mm, p= 0.09),
CRP (2.7 (2.8) vs 1.8 (3.7) mg/L, p= 0.36) or in the 29 cytokines
studied (Table 2).
However, the 28 JDM-active had 47.9% higher level of MCP-1
(35.5 (19.9) vs 24.0 (10.7) pg/ml, p = 0.012) than their matched
controls; between JDM-inactive and their controls, no such
difference in MCP-1 levels were seen (33.8 (24.2) vs 26.8 (12.2)
pg/ml, p = 0.18.
Associations between cytokines, age and disease
parameters at follow-up
Eotaxin and MCP-1 both correlated with disease duration
(r = 0.64 and r = 0.47, p’s,0.001, Table 3 and Figure 1) and age in
patients. However, when exploring the association between age
and serum cytokine levels in controls, no associations were found.
IP-10 correlated neither with disease duration nor with age in
patients or controls.
Both Eotaxin and MCP-1, but not IP-10, correlated with MDI
at follow-up (Table 3). High MCP-1 was associated with high
CRP, low SF-36 PCS, high CHAQ/HAQ and high cumulative
prednisolone dose. Eotaxin and MCP-1 intercorrelated stronger in
patients than in controls. No intercorrelation between IP-10 and
IFN-a was seen neither in patients nor in controls (r =20.12 and
r = 0.11). No correlations were seen neither between eotaxin,
MCP-1 nor IP-10 and disease activity (DAS) at follow-up. In a
multivariate linear regression analysis, MDI at follow-up was
associated with MCP-1 (standardized b=0.43, p = 0.002, R2 final
Table 1. Characteristics and disease parameters in 54 patients with juvenile dermatomyositis and in 54 controls.
Characteristics JDM patients Controls
Females 32 (59) 32 (59)
Age at symptom onset (years) 7.7 (1.4–17.3) NA
Age at diagnosis (years) 8.5 (2.1–19.3) NA
Variables assessed median 16.8 years after disease onset (follow-up)
Age (years) at follow-up 22.0 (6.7–55.4) 22.1 (6.2–55.4)
Duration from disease onset (years) 16.8 (2.0–38.1) NA
CRP (,4 mg/L) 2.3 (3.3) 1.4 (3.1)
ESR (,17 mm){ 7.0 (5.7) 5.7 (4.8)
SF 36 PCS` (0–100) 54.3 (26.9–60.9) 56.9 (32.1–63.7)*
CHAQ/HAQ (0–3) 0 (0–1.38) NA
MDI total (0–40) 3 (0–13) NA
DAS skin (0–9) 4 (0–7) NA
DAS muscle (0–11) 1 (0–8) NA
DAS total (0–20) 5 (0–13) NA
Prednisolone dosis, cumulative (g) 10.6 (12.3) NA
Prednisolone or DMARDs 16 (30) NA
Variables assessed 1 year post- diagnosis
MDI total (0–40) 1 (0–7) NA
DAS skin (0–9) 4 (0–8) NA
DAS muscle (0–11) 1 (0–7) NA
DAS total (0–20) 5 (0–15) NA
Values are number (%), median (range) or mean (SD). JDM: juvenile dermatomyositis; NA: not applicable; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate;
SF-36 PCS: Short Form 36 physical component Summary; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: disease modifying anti-rheumatic drugs; MDI:
Myositis Damage Index; DAS: Disease Activity Score.
*p,0.05.
`n= 46 pairs, only assessed in those .13 years;
{n= 50 pairs.
doi:10.1371/journal.pone.0092171.t001
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model = 40%), none of the control measures (age and gender)
were significant. A borderline significant association was seen
between MDI and eotaxin (standardized b=0.25, p = 0.054) in a
similar linear regression analysis.
Early predictors of elevated eotaxin and MCP-1 levels
MDI and DAS total assessed 1 year post-diagnosis, correlated
both with eotaxin and MCP-1 (Table 4). DAS skin, but not DAS
muscle correlated with eotaxin and borderline with MCP-1.
In a linear regression analysis, MDI 1 year post-diagnosis
predicted high MCP-1 (standardized b=0.29, p = 0.025). Of the
control measures, disease duration contributed significantly
(standardized b=0.32, p= 0.014), but not gender (R2 final model
= 34%).
Accordingly, MDI 1 year post-diagnosis also predicted high
eotaxin (standardized b=0.24, p = 0.049), both of the control
measures were significant (gender, standardized b=0.23,
p = 0.045; disease duration, standardized b=0.41, p = 0.001; R2
final model = 41%).
Discussion
In our study we have investigated cytokine abundance in JDM
patients and found, median 16.8 years after disease onset,
increased serum levels of eotaxin, MCP-1 and IP-10, compared
to matched controls. When stratified in JDM-active and JDM-
inactive, MCP-1 was elevated in JDM-active in comparison to
their respective controls; not in JDM-inactive compared to
controls. Eotaxin and MCP-1 both correlated with disease
duration, and increased levels were predicted by high score of
organ damage early in the disease course. MCP-1 was associated
with cumulative organ damage at follow-up. To our knowledge,
no other controlled study has investigated circulating cytokine
profile in an unselected JDM cohort after long-term follow up.
We have previously described the representativeness of our
cohort [2], which we believe contains the vast majority of
Norwegian JDM patients diagnosed between 1970 and 2006.
Our cohort is comparable with other hospital or registry based
cohorts with regards to female predominance, age at diagnosis,
medication and muscle weakness at disease onset [24,25]. The
representativeness of the patients and the sex- and age matching
with controls drawn randomly from the National Population
Register, represent strengths of our study.
We aimed at detecting differences in circulating levels of
cytokines in JDM patients compared to controls, and found a
significant increase in 3 and a numeric increase with p values of
0.06–0.08 for 5 of 28 cytokines. Eotaxin and MCP-1 correlated
with disease duration and therefore, necessarily with age. For
patients, age was substantially stronger correlated with eotaxin and
MCP-1 than for controls, indicating that the correlation between
disease duration and CC chemokines is not driven by aging per se.
In previous studies on cytokines, DM and JDM patients have been
investigated at time of diagnosis or early in disease course [8,9].
Increased serum levels of eotaxin, MCP-1 and IP-10, were found
in a study of 9 JDM patients with clinically active disease [26]. The
association between MCP-1 and active disease is supported by our
findings: when stratified according to the recently (2012) proposed
PRINTO criteria [10], differences in MCP-1 levels compared to
controls were seen in JDM-active but not in JDM-inactive.
Although we should be careful with our conclusions; we may have
been underpowered to detect differences between JDM-active and
JDM-inactive. However, the association with disease duration in
all patients suggests that eotaxin and MCP-1 may contribute to a
sustained inflammation and continue to play a role in JDM
throughout the disease course as well.
Table 2. Cytokine levels in patients with juvenile dermatomyositis assessed median 16.8 years after disease onset, and in controls.
JDM active JDM inactive All JDM Controls p value
MCP-1 35.5 (19.9) 33.8 (24.2) 34.7 (21.9) 25.3 (11.4) 0.006
IP-10 1598 (1631) 1361 (877) 1484 (1316) 1036 (475) 0.026
Eotaxin 150 (118) 133 (90) 142 (105) 108 (63.6) 0.039
IL-6 8.4 (14.1) 4.9 (4.0) 6.7 (10.6) 4.0 (2.0) 0.060
TNF-a 23.3 (25.7) 21.4 (18.0) 22.4 (22.2) 16.3 (7.2) 0.065
IL-13 2.7 (4.7) 2.8 (4.6) 2.8 (4.6) 1.6 (0.9) 0.078
IL-8 11.3 (3.3) 10.6 (2.0) 10.9 (2.7) 10.2 (2.2) 0.080
IL-1Ra 204 (396) 134 (140) 170 (301) 98.7 (61.5) 0.084
IFN-c 62.0 (86.8) 49.1 (43.5) 54.7 (70.5) 40.2 (20.9) 0.134
IL-10 6.1 (23.2) 3.5 (6.8) 4.8 (17.3) 1.7 (1.6) 0.183
IL-15 2.3 (3.1) 2.4 (3.0) 2.4 (3.0) 1.7 (1.7) 0.210
IL-18 422 (152) 415 (213) 419 (182) 391 (154) 0.336
TGF-b1 28000 (6770) 29900 (10700) 28900 (8860) 29500 (7360) 0.703
IL-4 2.1 (0.57) 2.1 (0.55) 2.1 (0.55) 2.0 (0.57) 0.794
IL-1b 0.96 (0.90) 1.1 (1.1) 1.0 (1.0) 1.0 (0.9) 0.946
Th1/Th2 27.6 (35.3) 23.8 (22.6) 25.8 (29.6) 19.7 (9.4) 0.780
IFN- a 11.9 (1.8) 11.1 (0.8) 11.5 (1.5) 12.0 (1.4) 0.07
Values for cytokine levels are mean (SD) pg/ml; n: all JDM= 54, controls = 54, JDM active = 28, JDM inactive = 26. p value when comparing cytokine levels in all JDM and
controls; for the comparison active vs inactive JDM, no differences were detected. The cytokines shown were selected based on associations seen in the present and/or
previous studies on dermatomyositis or other rheumatic diseases. JDM: juvenile dermatomyositis; MCP: monocyte chemoattractant protein; IP: interferon-inducible
protein; IL: interleukine; TNF: tumor necrosis factor; Ra: receptor antagonist; TGF: transforming growth factor; Th1/Th2, IFN-c/IL-4.
doi:10.1371/journal.pone.0092171.t002
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Figure 1. Correlations between monocyte chemoattractant protein-1 (MCP-1) (A and B) and eotaxin (C and D) and age, in 54
patients with juvenile dermatomyositis and sex- and age-matched controls. r, Spearman correlation coefficient.
doi:10.1371/journal.pone.0092171.g001
Table 3. Correlations between MCP-1, eotaxin and clinical and disease variables in patients with juvenile dermatomyositis
assessed median 16.8 years after disease onset, and in controls.
MCP-1 Eotaxin
Clinical variables Patients Controls Patients Controls
Male gender 0.37* 0.21 0.33* 0.39*
Age 0.54** 0.15 0.69** 0.27*
Disease duration 0.47** NA 0.64** NA
ESR 20.05 20.08 20.10 20.20
CRP 0.27* 0.15 0.09 0.01
Eotaxin 0.70** 0.56** NA NA
MDI 0.52** NA 0.52** NA
DAS total 0.25 NA 0.18 NA
DAS skin 0.17 NA 0.20 NA
DAS muscle 0.20 NA 0.09 NA
Prednisolone 0.28* NA 0.22 NA
SF 36 PCS 20.36* 0.09 20.24 0.11
CHAQ/HAQ 0.32* NA 0.21 NA
Values are r = Spearman correlation coefficient. MCP: monocyte chemoattractant protein; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MDI: Myositis
Damage Index; DAS: Disease Activity Score; Prednisolone: cumulative prednisolone dose during disease course; CHAQ: Childhood Health Assessment Questionnaire; SF-
36 PCS: Short Form 36 physical component Summary. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0092171.t003
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Several studies suggest a role of IFN-a activity in adult and
juvenile dermatomyositis [27,28]. Since IFN-a was comparable in
patients and controls, we did not analyze correlations with disease
parameters.
Our observation that eotaxin correlated with early DAS skin,
indicates a link between eotaxin and skin affection, in JDM. Some
studies associate eotaxin to fibrosis in different tissues as heart, liver
and lungs [29–31]. In JDM, eotaxin might induce similar tissue
fibrosis, either by recruiting granulocytes that release pro-fibrotic
substances, or by itself. Furthermore, we found a correlation
between eotaxin and organ damage (MDI) at follow-up, and in this
context a pro-fibrotic effect could be relevant. The increased
eotaxin and MCP-1 levels in patients could support a hypothesis of
low-grade sustained inflammation in JDM, contributing to
accumulate organ damage as suggested in juvenile idiopathic
arthritis [32]. Furthermore, correlation between eotaxin at follow-
up, and disease activity and organ damage at 1 year post-diagnosis
could indicate that this is a process initiated early in the course of
the disease.
It is reasonable to believe that JDM patients have a more
widespread and pronounced inflammation at the time of diagnosis
than at long-term follow-up. A large study from Sweden in 2010
showed that in rheumatoid arthritis (RA), many cytokines,
including eotaxin and MCP-1, were increased even before disease
onset, with further increase at the time of diagnosis [33]. In JDM,
a small study showed initial inflammation by measuring increased
serum level of IL-18 at time of diagnosis; the level then decreased
through the first year of the disease [23]. In our study, extensive
information about disease course was obtained through data from
patients with disease duration ranging from 2 to 38 years. It is
noteworthy that none of the cytokines showed a negative
correlation with disease duration as one perhaps might expect.
Whether there is a continuous increase in eotaxin abundance after
the initial active disease, remains unknown. Given the cross-
sectional nature of the study, we did not have data on the cytokine
levels from the initial years of the disease. One could speculate in a
biphasic response: a high initial level of eotaxin, then a decline
until, again, a steady climb after 2 years and onwards based on the
data in our study. This could be pursued by comparing our long-
term results with a prospective study with serial cytokine samples,
during the early phase of the disease.
MCP-1 is an attractor and activator of monocytes and T-
lymphocytes and is more studied than eotaxin. Besides being an
important actor in the immune response, MCP-1 is involved in
inflammation, angiogenesis and formation of atherosclerosis [34].
The angiogenetic effect is especially interesting since JDM is a
vasculopathy, this could be evaluated by capillaroscopy.
Homology between eotaxin and MCP-1 is 49% and they share
64% of the protein structure [35]; our data also show intercor-
relation between the two. Eotaxin is the natural agonist of CC
chemokine receptor 3 (CCR3), thus elevated circulating levels of
this chemokine may potentially increase the recruitment of CCR3-
expressing cells, thereby maintaining chronic inflammation.
However, eotaxin has also been shown to be a partial agonist of
the receptor CCR2 for which MCP-1 is a full agonist [36]. Thus,
eotaxin can partially block MCP-1 effects and could for instance
modulate monocyte recruitment in inflammatory condition which
is a main effect of MCP-1. Such interactions may well be present
in JDM, although this has not yet been studied.
MCP-1 correlated consistently with organ damage and early
disease activity and, as well as with other inflammatory parameters
such as CRP. Also, the association with cumulative prednisolone
dosis is interesting, possibly reflecting longstanding active disease.
In the DM/JDM patients studied by Bilgic et al [9], correlation
between MCP-1, IP-10, IL-6 and global disease activity was also
found the first two years of the disease. In our study, high early
organ damage predicted elevated levels of both eotaxin and MCP-
1. This suggests that eotaxin and MCP-1 measured at follow-up
could be useful biomarkers of disease outcome in JDM;
particularly since they are both associated with long-term
cumulative organ damage. Also since eotaxin and MCP-1 are
up regulated in the acute phase of JDM [26] one could speculate
that these cytokines could be early biomarkers of organ damage
late in disease course.
Eotaxin and MCP-1 may represent targets for biological
treatment in JDM. Anti-CCL2/MCP-1 [37], anti-CCL11/eotaxin
(bertilimumab) and CCR3 antagonist [38] are available and
potential treatment options. However, effects of cytokines are
diverse and complex. For example: in the literature, IP-10 is
considered as a type1 interferon (IFN-a) regulated cytokine [27],
despite this, we saw no correlations between IP-10 and IFN-a in
our study. Furthermore, one study showed no clinical improve-
ment in RA by blocking CCR2 [37], whereas another study on a
mouse model of RA surprisingly showed exacerbation of arthritis
when CCR2 was knocked out [39]. Thus, it is not obvious whether
modulation MCP-1 or eotaxin targets will have beneficial effects in
JDM, and interactions at receptor level between eotaxin and
MCP-1 can obscure interpretation of the results.
In conclusion; in 54 JDM patients seen median 16.8 years after
symptom onset, we have shown higher levels of eotaxin, MCP-1
and IP-10, compared to controls. On a subgroup level, increased
MCP-1 compared to controls was seen only in JDM-active, not in
JDM-inactive. Both eotaxin and MCP-1 correlated with disease
duration and organ damage; for IP-10, such correlations were not
seen. It is not clear whether eotaxin and MCP-1 per se cause
sustained inflammation and represent possible therapeutic targets.
They might also be markers for disease damage as a result of
disease activity caused by other unknown mechanisms. Either way,
Table 4. Correlations between MCP-1, eotaxin and disease variables in patients with juvenile dermatomyositis 1 year post -
diagnosis.
MCP-1 Eotaxin
r p value r p value
MDI 0.35 0.01 0.40 0.003
DAS total 0.28 0.039 0.36 0.007
DAS skin 0.27 0.053 0.36 0.008
DAS muscle 0.18 0.20 0.18 0.21
MCP: monocyte chemoattractant protein; r: Spearman correlation coefficient; MDI: Myositis Damage Index; DAS: Disease Activity Score.
doi:10.1371/journal.pone.0092171.t004
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the novel knowledge on these substances can improve insight and
treatment modalities of JDM.
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